Back to News
Market Impact: 0.18
Daiichi Sankyo Doses First Patient In Phase 1 Trial Of Novel CD25-Directed ADC DS1025
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsProduct Launches
Daiichi Sankyo dosed the first patient in a first-in-human Phase 1 trial for DS1025, a potential first-in-class CD25-directed antibody-drug conjugate (ADC) targeting advanced/metastatic solid tumors. While early-stage, the initiation of clinical evaluation is a positive development that may support longer-term R&D optionality.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary